Healthcare Webinars

Please note that this event is for Victorian residents only.This EDV Community Webinar is a 1 hour online workshop that will explore and aim to provide understanding of Perfectionism. This webinar is suitable for anyone currently experiencing or has recovered from an eating disorder, carers and support people, and those in the general community who are wanting to learn more about perfectionism.You can expect a balance of education and the opportunity for reflection, with a focus on the following topics: • Defining Perfectionism• Perfectionism and Eating Disorders• The Paradox of Perfectionism• Strategies to Manage PerfectionismYour facilitators:Emilie - Senior Education OfficerEmilie has worked within mental health services for twelve years with both adults and children both in the United Kingdom and Australia. Emilie is passionate about the importance of meaningful connection in her work and personal life, which was paramount in her own recovery of a severe and enduring eating disorder, and continues to be one of her core values. Abbey - Education OfficerAbbey has a background in public health and health promotion, and has worked in the mental health space for the past four years. Through experiencing and recovering from an eating disorder, Abbey realised her passion for raising awareness in the community about eating disorders and other mental health conditions, and is proud to be able to continue this work as part of the EDV Education Team. Shaan - Postgraduate Student, Master of Public HealthShaan is undertaking the final part of her Master of Public Health on placement at Eating Disorders Victoria. The work that EDV does sits close to Shaan’s heart, having herself experienced and recovered from an eating disorder. Shaan is excited to be bringing her public health knowledge and lived experience, along with four years’ public service experience in education, to the Education Team at EDV. WhenMonday September 9th, 2024 - 12:00pmWhere The webinar will take place via Zoom, with Zoom link details to be sent to attendees two hours prior to the event start time. Participants are not required to have their cameras or microphones on for this webinar, and are welcome to ask any questions anonymously throughout. This webinar will be recorded and will be made available to people who have registered for this webinarCostFree to attendEnquiriesFor more information or enquiries, please contact education@eatingdisorders.org.auYou will receive an email with the information on how to join 2 hours before the event. Please check your email, your junk email and any other email addresses that you might use. If you do not have an email then please contact us. The information you provide to Eating Disorders Victoria is for the purpose of contacting you about this event and to evaluate our services and client needs, with the view of improving our services. 

When sick children arrive at primary health care facilities, it is critical that they are appropriately screened, diagnosed, managed, and if needed, referred for urgent care without delay. Clinical signs alone do not detect all severe illness in children. For health care providers to make a correct diagnosis, they must be equipped with the right tools, including access to pulse oximetry and clinical decision support systems. In many countries, these critical tools are not available, not functioning properly, or providers lack appropriate training. There is also no clear global guidance to help countries in choosing the best devices, nor is information available on their cost-effectiveness or suitability in primary care.Between 2019 and 2024, the Tools for Integrated Management of Childhood Illness (TIMCI) initiative, led by PATH in collaboration with a consortium of partners and funded by Unitaid, worked together with the governments of India, Kenya, Senegal, and Tanzania to improve access to critical tools that help frontline health workers identify and appropriately manage children who are severely ill. This work included large-scale, multi-country, mixed-method evaluation conducted to address evidence gaps and inform national and international decision-making on scale-up of pulse oximetry and clinical decision support algorithms.Join us to review the cross-country results, interpretations, as well as key takeaways from the TIMCI studies, which can be helpful to decision-makers and implementers in further assessing national and global strategies for effectively embedding pulse oximetry and CDSAs as part of wider efforts to strengthen quality of care.

Churchill once said, “Out of intense complexities, intense simplicities emerge.”He meant that during challenging times, extreme focus reveals solutions right in front of companies. Despite ongoing tech investments, only 1 in 10 drugs gets commercialized, with costs soaring. Healthcare and life sciences companies are struggling and need future-proof ways to unlock organizational creativity. Worse, less than 20% of executives feel prepared to handle increasing complexities and challenges.What if you could connect people, departments, functions, and ecosystems to drive successful outcomes with a unified digital foundation? What if you could reignite innovation, reach more patients, and control costs?Introducing ServiceNow’s Digital Health Platform: a unified, industry-centric solution enabling H&LS customers to meet global disruption challenges.Save your seat and learn how to advance life sciences by leveraging EY’s expertise and ServiceNow’s transformative offerings.

Sign up for the webinar and join Mr. Michael Horler, Mrs. Samantha Mann, and Prof. Tunde Peto as they discuss the inclusion of the OCT pathway in DESP and its benefits and challenges.Program• Introduction – Mr. Michael Horler• The New OCT Pathway: Why Was Adding This Pathway Necessary? | Mrs. Samantha Mann• Cases 1-2: Representative Cases | Mrs. Samantha Mann and Prof. Tunde Peto• The South London Experience | Mrs. Samantha Mann• Case 3: From South London | Mrs. Samantha Mann• Analysing OCT Images and Getting Ready for the DESP Pathway Change | Prof. Tunde Peto• Cases 4-5: The One Where the Pathway Will Help and the One Where It Will Not! | Prof. Tunde Peto• Live Q&A moderated by Mr. Michael HorlerWhy should you attend?• Discover how OCT will change diabetic eye screening• Get practical tips and learn how to interpret OCT images• Get more insights into what OCT is• Participate in the live Q&A to find answers to your questionsSpeakers: Mrs. Samantha Mann, MD MRCOph FRCOph and Prof. Tunde Peto, MD, PhD.------------Prepare for the integration of the OCT pathway into the English National Diabetic Eye Screening Programme (DESP) and join our webinar on September 4 at 6 pm (UK time) / 7 pm (CEST).This 90-minute event, made possible by the Canon Medical Academy, will cover the benefits, challenges, and essential training for accurate OCT image grading.Designed by eye care professionals for eye care professionals, this event is crucial for mastering advancements in diabetic retinopathy management. The inclusion of the OCT pathway in DESP represents a significant leap in diabetic eye care, offering more efficient and accurate screening while reducing the pressure on hospital eye services.Register now to improve your skills and stay ahead in retinal screening with our expert-led webinar.

For patients with advanced non-small cell lung cancer (NSCLC), tissue samples are typically small biopsies. These samples undergo standard of care evaluation for >10 biomarkers to identify targeted, personalized therapies. If only single-gene tests are ordered, it is unlikely all biomarkers will be successfully tested. Furthermore, the patient may not be able to get a second biopsy for comprehensive testing. Ordering single-gene tests before comprehensive profiling creates longer wait times for results, which can be problematic for selecting optimal treatment.Join Drs. Kyle C. Strickland and Rebecca A. Previs from Labcorp Oncology’s Medical Affairs team for this webinar to hear about tissue stewardship from a pathologist and oncologist’s perspectives. We will review our latest data from advanced NSCLC which demonstrate that single-gene testing, if performed prior to comprehensive genomic profiling, doubles comprehensive genomic profiling failures due to tissue insufficiency and DNA extraction failures. We will share best practices to optimize tissue utilization and ensure patients with advanced NSCLC receive all recommended biomarker testing.Learning Objectives:• Describe the various tissue testing methodologies available for evaluation of biomarkers for patients with advanced NSCLC.• Compare biomarker testing paradigms with single gene testing and comprehensive genomic profiling to describe benefits and pitfalls of each strategy.• Integrate best practices for tissue stewardship to optimize biomarker testing in advanced NSCLC.Speakers: Kyle Strickland, MD, PhD (Labcorp Oncology, Director, Medical Affairs and Adjunct Associate Professor, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Labcorp), Rebecca Previs, MD, MS (Labcorp Oncology, Director, Medical Affairs and Adjunct Assistant Professor, Duke University Medical Center, Duke Cancer Institute, Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Labcorp).

Manufacturing cell and gene therapy products is complex and involves multiple challenges, including a unique combination of expensive cell culture solutions and experience. It is crucial to keep the end product in mind from the beginning in order to expedite processes and ensure a seamless scale-up, while reducing costs. Optimizing cell culture media and buffers to fit your process allows you to enhance experimental conditions, improve cell performance, and achieve more reliable and reproducible results in your studies.  In this webinar, our experts will discuss the importance of optimized cell media and buffers using the design of classical media formulations to demonstrate the importance of component selection in the formulation process. Our collaborators at University of Pennsylvania and SK pharmteco will explain how media and buffer design has optimized their processes and improved outcomes. You will learn how cell media and buffers can impact cell growth, viability, and therapeutic efficacy as well as strategies to simplify custom media and buffer design and optimization for all stages of development and manufacturing.  Key Takeaways: • Understand how customized media and buffers can optimize CQAs in C&GT. • Explore real-world case studies demonstrating the impact of customized solutions. • Gain practical insights into improving bioprocess development and consistency. Speakers: Asma Ayari, Ph.D., Director of Research and Development, Nucleus Biologics; John Bowen, Ph.D., Senior Director of Nucleic Acids and Plasmid Operations, SK pharmteco; Roddy O’Connor, Ph.D., Research Assistant Professor, Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine.

The viral vector market, which is crucial for vaccines and gene therapies, is experiencing rapid growth. Essential factors to produce viral vectors needed for clinical trials and commercial manufacturing include scalability in transitioning from process development to commercial production and the simplicity of operating the culture device. Thermo Fisher Scientific's ThermoScientific DynaDrive Single-Use Bioreactor (S.U.B.) is a versatile bioreactor that can cultivate cells used for AAV production across a wide range of volumes, from 50 L to 5,000 L.In this seminar, representatives from both Takara Bio and Thermo Fisher Scientific, key players invigorating the gene therapy market, will explain the features of single-use bioreactors that enable mass manufacturing of AAV vectors. Additionally, they will present case studies with data that highlight the successful viral vector manufacturing process.Speakers: Hideto Chono, Ph.D. serves as the Deputy Head of CDM Business Development Division and General Manager at Takara Bio Inc. He holds a Ph.D. in Agriculture from Kyoto University and has been with Takara since 1992. He specializes in the research, development, and manufacturing of viral vectors, mRNAs, and engineered T-cells.Hiroshi Nagasaki, Ph.D. is a Field Application Scientist at Thermo Fisher Scientific K.K. in Japan. With 13 years of experience at the company, Hiroshi leads a team of Field Application Scientists specializing in BioProduction. He holds a Ph.D. in agriculture from Nagoya University. Hiroshi's expertise and leadership have been instrumental in providing support to customers.

Join us for a sponsored webinar featuring Cytovale’s IntelliSep sepsis test where we will talk about how this novel technology is changing the way patients are triaged in the ED, leading to faster, more accurate detection of sepsis and appropriate care. You will learn insights into what makes sepsis so challenging to diagnose and how IntelliSep can help. You will also meet leaders from Our Lady of the Lake Regional Medical Center, including Dr. Hollis O’Neal, who will share the impact that IntelliSep has had on their patients, day-to-day processes, and the organization broadly. For more information, visit our website cytovale.com.Target Audience: Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.Speaker: Hollis (Bud) O'Neal, MD (Associate Professor of Medicine, Louisiana State University Health Sciences Center).

In this webinar, find out how to optimise oncology clinical trials using digital tools to accelerate decision-making.Oncology clinical trials present some of the most complex challenges across clinical research, impacting enrolment, efficiency, and access. Thankfully, our industry is afforded a unique opportunity to address these issues with the evolving regulatory landscape, the burgeoning field of digital health technologies (DHTs), and the increasing adoption of decentralised and digital trial methods.The US Food and Drug Administration (FDA)’s recent guidance on Direct-to-Patient (DTP) approaches, electronic Patient-Reported Outcomes (ePROs), and DHTs paves the way for incorporating patient-centric digital tools into trials.According to PwC, the use of DHTs in clinical trials has grown by 97 percent within the last five years, and Tufts recognises that the appetite for collecting digital endpoints has doubled every three years since 2015.As DHTs begin to help researchers define the new normal, it’s important to have the right strategy to define how you collect the right data to improve efficiency and experience. Learn how top 10 pharmaceutical companies are using a combination of DHTs, ePROs, clinical trial platforms and more, to ease oncology research and drastically reduce timelines. Key learning points- The right questions to ask your team to help define a digital strategy as part of your clinical development programme. - Why the expanded use of digital measures and biomarkers will continue to accelerate clinical development timelines.- How global pharmaceutical companies are benefiting from Medable’s novel approaches and technology to accelerate decision-making in oncology.Speaker: Musaddiq Khan – Vice President, Customer Value – Digital Outcomes & TA Strategy at Medable

Under U.S. critical infrastructure policy coordinated by the U.S. Department of Homeland Security Cybersecurity and Infrastructure Security Agency (CISA), Healthcare is designated among 15 other industry sectors as “critical infrastructure” and is represented by an industry-organized “sector coordinating council (SCC).” The Health Sector Coordinating Council (HSCC) is a public-private partnership working directly with the U.S. Department of Health and Human Services (including FDA) and focused on providing cybersecurity practices, resources, and advocacy specific to the healthcare sector.How might HSCC participation provide value for your organization’s cybersecurity strategy? HSCC mission is to identify systemic cybersecurity threats; collaborate on guidance and policies for mitigating those risks; and promote threat preparedness and incident response awareness and activities across the sector.In this webinar, Greg Garcia, HSCC Executive Director, will provide an overview of the work done by HSCC, review some specific examples of resources produced by working groups, and discuss HSCC’s recently announced 5-year strategic plan.Attendees will:• Understand HSCC objectives, structure, and strategic plan• Recognize the HSCC work products through provided examples• Evaluate if HSCC participation could be valuable to your organization